Certican Tablet

Introduction

Certican Tablet 0.75 mg is an orally administered mTOR inhibitor, which is a type of antineoplastic drug. It is used to treat advanced renal cell carcinoma (RCC) and subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC). It is believed to act by inhibiting mTOR, the target of rapamycin, a protein involved in the regulation of cell cycle progression, proliferation, angiogenesis, and metabolism.

Uses

Certican Tablet 0.75 mg is used to treat advanced renal cell carcinoma (RCC) and subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC).

Brand Name	Certican
Type	Tablet
Weight	0.75 mg
Generic	Everolimus
Manufacturer	Novartis (Bangladesh) Ltd.
Available in	English বাংলা

Mechanism of Action

Certican Tablet 0.75 mg works by inhibiting mTOR, the target of rapamycin, a protein involved in the regulation of cell cycle progression, proliferation, angiogenesis, and metabolism.

How Long Does It Take to Work?

Certican Tablet 0.75 mg usually begins to work within the first few weeks of treatment, with the effects becoming more noticeable over time. Patients treated with Certican Tablet 0.75 mg may experience improvement in symptoms within 8-12 weeks.

Absorption

Certican Tablet 0.75 mg is rapidly and almost completely absorbed following oral administration.

Route of Elimination

Certican Tablet 0.75 mg is primarily eliminated via the bile.

Dosage

Everolimus are two different dosage forms. Select the recommended dosage form based on the indication. Do not combine Everolimus to achieve the total dose. Modify the dosage for patients with hepatic impairment or for patients taking drugs that inhibit or induce P glycoprotein (P-gp) and CYP3A4.

Hormone Receptor-Positive, HER2-Negative Breast Cancer: The recommended dosage of Everolimus is 10 mg orally once daily until disease progression or unacceptable toxicity.

Neuroendocrine Tumors (NET): The recommended dosage of Everolimus is 10 mg orally once daily until disease progression or unacceptable toxicity.

Renal Cell Carcinoma (RCC): The recommended dosage of Everolimus is 10 mg orally once daily until disease progression or unacceptable toxicity.

Tuberous Sclerosis Complex (TSC): Associated Renal Angiomyolipoma: The recommended dosage of Everolimus is 10 mg orally once daily until disease progression or unacceptable toxicity.

Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA): The recommended starting dosage of Everolimus is 4.5 mg/m2 orally once daily until disease progression or unacceptable toxicity.

Tuberous Sclerosis Complex (TSC)-Associated Partial-Onset Seizures: The recommended starting dosage of Everolimus is 5 mg/m2 orally once daily until disease progression or unacceptable toxicity.

For the treatment of advanced RCC, the recommended dosage of Certican Tablet 0.75 mg is 10 mg orally once daily.

Administration

Certican Tablet 0.75 mg should be taken orally, once daily, with or without food.

Side Effects

Common side effects of Certican Tablet 0.75 mg include fatigue, diarrhea, anemia, nausea, stomatitis, asthenia, constipation, decreased appetite, fever, infection, vomiting, cough, mucositis, abdominal pain, and rash.

Toxicity

Certican Tablet 0.75 mg is generally well-tolerated; the most severe toxicities associated with its use are infections and gastrointestinal inflammation. Other side effects that may occur include hypercholesterolemia, hypertension, hypertriglyceridemia, hypophosphatemia, hyperglycemia, and hypokalemia.

Precaution

Patients should be monitored closely for signs and symptoms of infection while taking Certican Tablet 0.75 mg and should be instructed to contact their healthcare provider for any symptoms. Patients may also be at risk of developing severe and potentially fatal complications associated with the use of Certican Tablet 0.75 mg, including interstitial lung disease, hepatotoxicity, and immune-mediated events.

Interactions

Certican Tablet 0.75 mg can interact with a variety of medications and other drugs, and patients should discuss any potential drug interactions with their healthcare provider. Patients should also be aware of potential food–drug interactions and should avoid eating grapefruit or drinking grapefruit juice while taking Certican Tablet 0.75 mg.

Disease Interaction

Certican Tablet 0.75 mg may interact with certain medical conditions, and should be taken with caution in patients with a history of diabetes mellitus, cholestasis, hepatic impairment, severe infections, or autoimmune diseases.

Drug Interactions

Certican Tablet 0.75 mg may interact with certain drugs, and should not be taken with ACE inhibitors, cyclosporine, hypotension-inducing agents, or specific antifungal agents.

Food Interactions

Grapefruit and grapefruit juice should be avoided while taking Certican Tablet 0.75 mg.

Pregnancy Use

Certican Tablet 0.75 mg is not recommended for use in pregnant women. Animal studies have not shown any evidence of fetal harm, but the potential risks to humans are not known.

Lactation Use

Certican Tablet 0.75 mg is not recommended for use in nursing mothers. It is not known whether Certican Tablet 0.75 mg is excreted in breast milk, and the potential risks to an infant are not known.

Acute Overdose

The most commonly reported symptoms following an Certican Tablet 0.75 mg overdose are fatigue, dizziness, and nausea. If an overdose is suspected, it is important to contact a healthcare provider immediately for appropriate medical care.

Contraindication

Certican Tablet 0.75 mg is contraindicated in patients with a history of hypersensitivity to Certican Tablet 0.75 mg or its excipients.

Use Direction

Take Certican Tablet 0.75 mg by mouth, once daily, with or without food. Swallow the capsule whole with water. Do not break, crush, or chew the capsule. Take your Certican Tablet 0.75 mg at the same time each day.